{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T15:32:09Z","timestamp":1787671929947,"version":"build-2736575974"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      A combination of mefloquine associated with artesunate (AS-MQ) was the first artemisinin-based combination therapy (ACT) to be used widely for acute uncomplicated\n                      <jats:italic>P. falciparum<\/jats:italic>\n                      malaria.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Individual patient data from 31 studies of patients with uncomplicated falciparum malaria treated with various AS-MQ regimens (target mefloquine dose 25\u00a0mg\/kg), conducted in Asia, Africa and South America, were pooled and analysed to investigate the effects of MQ mg\/kg dosing on malaria recurrence and other clinical, parasitological and tolerability endpoints.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 6,761 patients were enrolled in clinical studies conducted between 1995 and 2018; the majority (74%) were from Asia. The median age of study participants was 18\u00a0years (interquartile range IQR 8\u201330\u00a0years), of whom 13.5% (915\/6761) were aged less than 5\u00a0years old. Participants received an estimated median [range] total mg\/kg dose of mefloquine and artesunate of 25 [6.8\u201360] and 12 [3.6\u201333.3] respectively, and 1,572 (23.4%) participants were treated with the coformulation.<\/jats:p>\n                    <jats:p>The PCR-corrected recrudescence rate 42\u00a0days after any ASMQ treatment was 2.4% for patients enrolled in Asia and 2.5% in Africa, before artemisinin resistance emerged. Corresponding rates in children aged 1 to\u2009&lt;\u20095\u00a0years were 2.9% and 3.3%. After adjusting for background artemisinin resistance, the hazard of recrudescence was higher in children aged 1 to\u2009&lt;\u20095\u00a0years than in adults in Asia, but not in Africa (Asia, HR 3.01, 95%CI 1.60\u20135.64, p\u2009&lt;\u20090.001; Africa HR 5.18, 95% CI 0.61\u201344.28, p\u2009=\u20090.133). There was only one recrudescent infection in South America. A significant MQ dose\u2013effect was observed in Asia in patients treated with 3-dose regimens (AHR 0.89, 95% CI 0.83\u20130.96, p\u2009=\u20090.003 for 1\u00a0mg\/kg increase in dose).<\/jats:p>\n                    <jats:p>Vomiting rates within an hour of dosing were highest in children 1- 5\u00a0years of age (n\u2009=\u2009140) at 3.4% doses (13\/378) compared to 1.7% (20\/1,168) in children 5\u201311\u00a0years (n\u2009=\u2009476), and 1.1% (47\/4,191) in patients 12\u00a0years of age or older (n\u2009=\u20092027) (p\u2009&lt;\u20090.001, test for trend).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>AS-MQ administered over three days is a highly efficacious ACT in low to moderate transmission areas without artemisinin resistance. While further optimisation of the mefloquine dose in the coformulation in children aged 1\u20135\u00a0years could be considered, dose-related early vomiting is highest in this age group and may preclude this.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12936-026-05963-4","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T02:39:33Z","timestamp":1787625573000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The effect of mefloquine dose on outcome of uncomplicated falciparum malaria treated with artesunate-mefloquine: a WWARN systematic review and individual patient data meta-analysis"],"prefix":"10.1186","volume":"25","author":[{"name":"The WWARN AS-MQ Dose Impact Study Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.","family":"Ashley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Baron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marielle K.","family":"Bouyou-Akotet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebekah","family":"Burrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwenaelle","family":"Carn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Verena I.","family":"Carrara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Comets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal","family":"Csajka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"D\u2019Alessandro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas P.","family":"Day","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdoulaye A.","family":"Djimde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjen","family":"Dondorp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Duparc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MAbul","family":"Faiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo Urbano","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Fleckenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oumar","family":"Gaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blaise","family":"Genton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe J.","family":"Guerin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva Maria","family":"Hodel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgina S.","family":"Humphreys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter G.","family":"Kremsner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srivicha","family":"Krudsood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Ladeia-Andrade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilbert","family":"Lef\u00e8vre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashid","family":"Mansoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayfong","family":"Mayxay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul N.","family":"Newton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois","family":"Nosten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aung Pyae","family":"Phyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ric N.","family":"Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sasithon","family":"Pukrittayakamee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Ramharter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronnatrai","family":"Rueangweerayut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Issaka","family":"Sagara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sodiomon B.","family":"Sirima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank M.","family":"Smithuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kasia","family":"Stepniewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter R. J.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Innocent","family":"Val\u00e9a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neena","family":"Valecha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid V. F.","family":"van den Broek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob W.","family":"van der Pluijm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mich\u00e8le","family":"van Vugt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen A.","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,25]]},"reference":[{"key":"5963_CR1","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1093\/infdis\/166.6.1393","volume":"166","author":"FO ter Kuile","year":"1992","unstructured":"ter Kuile FO, Nosten F, Thieren M, Luxemburger C, Edstein MD, Chongsuphajaisiddhi T, et al. High-dose mefloquine in the treatment of multidrug-resistant falciparum malaria. J Infect Dis. 1992;166:1393\u2013400.","journal-title":"J Infect Dis"},{"key":"5963_CR2","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1093\/infdis\/170.4.971","volume":"170","author":"F Nosten","year":"1994","unstructured":"Nosten F, Luxemburger C, ter Kuile FO, Woodrow C, Eh JP, Chongsuphajaisiddhi T, et al. Treatment of multidrug-resistant Plasmodium falciparum malaria with 3-day artesunate-mefloquine combination. J Infect Dis. 1994;170:971\u20137.","journal-title":"J Infect Dis"},{"key":"5963_CR3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0004551","volume":"4","author":"VI Carrara","year":"2009","unstructured":"Carrara VI, Zwang J, Ashley EA, Price RN, Stepniewska K, Barends M, et al. Changes in the treatment responses to artesunate-mefloquine on the northwestern border of Thailand during 13 years of continuous deployment. PLoS ONE. 2009;4:e4551.","journal-title":"PLoS ONE"},{"key":"5963_CR4","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1128\/AAC.00040-06","volume":"50","author":"EA Ashley","year":"2006","unstructured":"Ashley EA, Stepniewska K, Lindegardh N, McGready R, Hutagalung R, Hae R, et al. Population pharmacokinetic assessment of a new regimen of mefloquine used in combination treatment of uncomplicated falciparum malaria. Antimicrob Agents Chemother. 2006;50:2281\u20135.","journal-title":"Antimicrob Agents Chemother"},{"key":"5963_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-12-68","volume":"12","author":"S Wells","year":"2013","unstructured":"Wells S, Diap G, Kiechel JR. The story of artesunate-mefloquine (ASMQ), innovative partnerships in drug development: case study. Malar J. 2013;12:68.","journal-title":"Malar J"},{"key":"5963_CR6","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1093\/trstmh\/trad069","volume":"118","author":"BS de Freitas","year":"2024","unstructured":"de Freitas BS, Fernandes GH, Pereira A, Peixoto HM. Artesunate-mefloquine therapy for uncomplicated Plasmodium falciparum malaria: an updated systematic review and meta-analysis of efficacy and safety. Trans R Soc Trop Med Hyg. 2024;118:84\u201394.","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"5963_CR7","doi-asserted-by":"crossref","unstructured":"Bukirwa H, Orton L. Artesunate plus mefloquine versus mefloquine for treating uncomplicated malaria. Cochrane Database Syst Rev. 2005;2005:Cd004531.","DOI":"10.1002\/14651858.CD004531.pub2"},{"key":"5963_CR8","doi-asserted-by":"publisher","first-page":"264","DOI":"10.2165\/00003088-199019040-00002","volume":"19","author":"J Karbwang","year":"1990","unstructured":"Karbwang J, White NJ. Clinical pharmacokinetics of mefloquine. Clin Pharmacokinet. 1990;19:264\u201379.","journal-title":"Clin Pharmacokinet"},{"key":"5963_CR9","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/S0009-9236(99)70010-X","volume":"66","author":"JA Simpson","year":"1999","unstructured":"Simpson JA, Price R, ter Kuile F, Teja-Isavatharm P, Nosten F, Chongsuphajaisiddhi T, et al. Population pharmacokinetics of mefloquine in patients with acute falciparum malaria. Clin Pharmacol Ther. 1999;66:472\u201384.","journal-title":"Clin Pharmacol Ther"},{"key":"5963_CR10","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s12916-016-0621-7","volume":"14","author":"WWARN Gametocyte Study Group","year":"2016","unstructured":"WWARN Gametocyte Study Group. Gametocyte carriage in uncomplicated Plasmodium falciparum malaria following treatment with artemisinin combination therapy: a systematic review and meta-analysis of individual patient data. BMC Med. 2016;14:79.","journal-title":"BMC Med"},{"key":"5963_CR11","first-page":"631","volume":"73","author":"FO ter Kuile","year":"1995","unstructured":"ter Kuile FO, Nosten F, Luxemburger C, Kyle D, Teja-Isavatharm P, Phaipun L, et al. Mefloquine treatment of acute falciparum malaria: a prospective study of non-serious adverse effects in 3673 patients. Bull World Health Organ. 1995;73:631\u201342.","journal-title":"Bull World Health Organ"},{"key":"5963_CR12","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1080\/02724936.1996.11747839","volume":"16","author":"C Luxemburger","year":"1996","unstructured":"Luxemburger C, Price RN, Nosten F, Ter Kuile FO, Chongsuphajaisiddhi T, White NJ. Mefloquine in infants and young children. Ann Trop Paediatr. 1996;16:281\u20136.","journal-title":"Ann Trop Paediatr"},{"key":"5963_CR13","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/S0035-9203(98)90916-6","volume":"92","author":"C Luxemburger","year":"1998","unstructured":"Luxemburger C, van Vugt M, Slight T, Price RN, Chongsuphajaisiddhi T, Chanthavanich P, et al. Early vomiting of mefloquine in children with malaria is not modified by the timing of antipyretic treatment. Trans R Soc Trop Med Hyg. 1998;92:562\u20133.","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"5963_CR14","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1111\/j.1708-8305.1999.tb00843.x","volume":"6","author":"P Schlagenhauf","year":"1999","unstructured":"Schlagenhauf P. Mefloquine for malaria chemoprophylaxis 1992\u20131998: a review. J Travel Med. 1999;6:122\u201333.","journal-title":"J Travel Med"},{"key":"5963_CR15","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1186\/1475-2875-9-357","volume":"9","author":"P Schlagenhauf","year":"2010","unstructured":"Schlagenhauf P, Adamcova M, Regep L, Schaerer MT, Rhein HG. The position of mefloquine as a 21st century malaria chemoprophylaxis. Malar J. 2010;9:357.","journal-title":"Malar J"},{"key":"5963_CR16","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.ijpddr.2014.03.002","volume":"4","author":"RL Nevin","year":"2014","unstructured":"Nevin RL. Idiosyncratic quinoline central nervous system toxicity: historical insights into the chronic neurological sequelae of mefloquine. Int J Parasitol Drugs Drug Resist. 2014;4:118\u201325.","journal-title":"Int J Parasitol Drugs Drug Resist"},{"key":"5963_CR17","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.tmaid.2017.10.011","volume":"20","author":"M Tickell-Painter","year":"2017","unstructured":"Tickell-Painter M, Saunders R, Maayan N, Lutje V, Mateo-Urdiales A, Garner P. Deaths and parasuicides associated with mefloquine chemoprophylaxis: a systematic review. Travel Med Infect Dis. 2017;20:5\u201314.","journal-title":"Travel Med Infect Dis"},{"key":"5963_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0168780","volume":"12","author":"SJ Lee","year":"2017","unstructured":"Lee SJ, Ter Kuile FO, Price RN, Luxemburger C, Nosten F. Adverse effects of mefloquine for the treatment of uncomplicated malaria in Thailand: a pooled analysis of 19, 850 individual patients. PLoS ONE. 2017;12:e0168780.","journal-title":"PLoS ONE"},{"key":"5963_CR19","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/S1473-3099(16)30125-6","volume":"16","author":"AC Eziefula","year":"2016","unstructured":"Eziefula AC. Artesunate-mefloquine: a malaria treatment for African children? Lancet Infect Dis. 2016;16:1086\u20137.","journal-title":"Lancet Infect Dis"},{"key":"5963_CR20","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature12876","volume":"505","author":"F Ariey","year":"2014","unstructured":"Ariey F, Witkowski B, Amaratunga C, Beghain J, Langlois AC, Khim N, et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature. 2014;505:50\u20135.","journal-title":"Nature"},{"key":"5963_CR21","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/S0140-6736(04)16767-6","volume":"364","author":"RN Price","year":"2004","unstructured":"Price RN, Uhlemann AC, Brockman A, McGready R, Ashley E, Phaipun L, et al. Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number. Lancet. 2004;364:438\u201347.","journal-title":"Lancet"},{"key":"5963_CR22","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw388","author":"AP Phyo","year":"2003","unstructured":"Phyo AP, Ashley EA, Anderson TJ, Bozdech Z, Carrara VI, Sriprawat K, et al. Declining efficacy of artemisinin combination therapy against P. falciparum malaria on the Thai-Myanmar border (2003-2013): the role of parasite genetic factors. Clin Infect Dis. 2003. https:\/\/doi.org\/10.1093\/cid\/ciw388.","journal-title":"Clin Infect Dis"},{"key":"5963_CR23","unstructured":"The effect of dose on the antimalarial efficacy of artesunate-mefloquine against plasmodium falciparum malaria: a systematic review and individual patient data (IPD) meta-analysis. https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?ID=CRD42018103776"},{"key":"5963_CR24","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-027738","volume":"9","author":"R Mansoor","year":"2019","unstructured":"Mansoor R, Dahal P, Humphreys GS, Guerin P, Ashley EA, Stepniewska K. The effect of dose on the antimalarial efficacy of artesunate-mefloquine against Plasmodium falciparum malaria: a protocol for systematic review and individual patient data (IPD) meta-analysis. BMJ Open. 2019;9:e027738.","journal-title":"BMJ Open"},{"key":"5963_CR25","doi-asserted-by":"publisher","first-page":"359","DOI":"10.4269\/ajtmh.19-0706","volume":"103","author":"J Takata","year":"2020","unstructured":"Takata J, Sondo P, Humphreys GS, Burrow R, Maguire B, Hossain MS, et al. The WorldWide Antimalarial Resistance Network Clinical Trials Publication Library: a live, open-access database of Plasmodium treatment efficacy trials. Am J Trop Med Hyg. 2020;103:359\u201368.","journal-title":"Am J Trop Med Hyg"},{"key":"5963_CR26","unstructured":"IDDO Data Access Committee. https:\/\/www.iddo.org\/governance\/data-access-committee"},{"key":"5963_CR27","unstructured":"World Health Organization. Weight-for-age. https:\/\/www.who.int\/tools\/child-growth-standards\/standards\/weight-for-age"},{"key":"5963_CR28","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1186\/1475-2875-10-378","volume":"10","author":"PW Gething","year":"2011","unstructured":"Gething PW, Patil AP, Smith DL, Guerra CA, Elyazar IR, Johnston GL, et al. A new world malaria map: Plasmodium falciparum endemicity in 2010. Malar J. 2011;10:378.","journal-title":"Malar J"},{"key":"5963_CR29","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1093\/femsre\/fuw037","volume":"41","author":"CJ Woodrow","year":"2017","unstructured":"Woodrow CJ, White NJ. The clinical impact of artemisinin resistance in Southeast Asia and the potential for future spread. FEMS Microbiol Rev. 2017;41:34\u201348.","journal-title":"FEMS Microbiol Rev"},{"key":"5963_CR30","doi-asserted-by":"publisher","first-page":"429","DOI":"10.2307\/2986270","volume":"43","author":"P Royston","year":"1994","unstructured":"Royston P, Altman DG. Regression using fractional polynomials of continuous covariates: parsimonious parametric modelling. Appl Stat. 1994;43:429\u201367.","journal-title":"Appl Stat"},{"key":"5963_CR31","unstructured":"GRADE handbook. https:\/\/gdt.gradepro.org\/app\/handbook\/handbook.html"},{"key":"5963_CR32","unstructured":"Cochrane Risk of Bias 2 (RoB 2) tool. https:\/\/methods.cochrane.org\/risk-bias-2"},{"key":"5963_CR33","unstructured":"World Health Organization: WHO Guidelines for malaria. Geneva. 2023."},{"key":"5963_CR34","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1111\/j.1365-3156.2006.01690.x","volume":"11","author":"MB Denis","year":"2006","unstructured":"Denis MB, Tsuyuoka R, Poravuth Y, Narann TS, Seila S, Lim C, et al. Surveillance of the efficacy of artesunate and mefloquine combination for the treatment of uncomplicated falciparum malaria in Cambodia. Trop Med Int Health. 2006;11:1360\u20136.","journal-title":"Trop Med Int Health"},{"key":"5963_CR35","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1128\/AAC.00040-06","volume":"50","author":"EA Ashley","year":"2006","unstructured":"Ashley EA, Stepniewska K, Lindeg\u00e5rdh N, McGready R, Hutagalung R, Hae R, et al. Population pharmacokinetic assessment of a new regimen of mefloquine used in combination treatment of uncomplicated falciparum malaria. Antimicrob Agents Chemother. 2006;50:2281\u20135.","journal-title":"Antimicrob Agents Chemother"},{"key":"5963_CR36","unstructured":"U.S. Centers for Disease Control and Prevention. Clinical Guidance: Malaria Diagnosis & Treatment in the U.S. https:\/\/www.cdc.gov\/malaria\/hcp\/clinical-guidance\/malaria-treatment-tables.html"},{"key":"5963_CR37","doi-asserted-by":"publisher","first-page":"e20","DOI":"10.1016\/S1473-3099(19)30426-8","volume":"20","author":"I Felger","year":"2020","unstructured":"Felger I, Snounou G, Hastings I, Moehrle JJ, Beck HP. PCR correction strategies for malaria drug trials: updates and clarifications. Lancet Infect Dis. 2020;20:e20\u20135.","journal-title":"Lancet Infect Dis"},{"key":"5963_CR38","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/s41579-024-01008-2","volume":"22","author":"PJ Rosenthal","year":"2024","unstructured":"Rosenthal PJ, Asua V, Conrad MD. Emergence, transmission dynamics and mechanisms of artemisinin partial resistance in malaria parasites in Africa. Nat Rev Microbiol. 2024;22:373\u201384.","journal-title":"Nat Rev Microbiol"},{"key":"5963_CR39","doi-asserted-by":"crossref","unstructured":"Grossman T, Vainer J, Paran Y, Studentsky L, Manor U, Dzikowski R, Schwartz E. Emergence of artemisinin-based combination treatment failure in patients returning from sub-Saharan Africa with P. falciparum malaria. J Travel Med. 2023;30.","DOI":"10.1093\/jtm\/taad114"},{"key":"5963_CR40","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.pt.2020.09.011","volume":"37","author":"RW van der Pluijm","year":"2021","unstructured":"van der Pluijm RW, Amaratunga C, Dhorda M, Dondorp AM. Triple artemisinin-based combination therapies for malaria\u2014a new paradigm? Trends Parasitol. 2021;37:15\u201324.","journal-title":"Trends Parasitol"},{"key":"5963_CR41","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1080\/14740338.2018.1535593","volume":"17","author":"M Saito","year":"2018","unstructured":"Saito M, Gilder ME, McGready R, Nosten F. Antimalarial drugs for treating and preventing malaria in pregnant and lactating women. Expert Opin Drug Saf. 2018;17:1129\u201344.","journal-title":"Expert Opin Drug Saf"},{"key":"5963_CR42","volume":"11","author":"R Gonz\u00e1lez","year":"2018","unstructured":"Gonz\u00e1lez R, Pons-Duran C, Piqueras M, Aponte JJ, Ter Kuile FO, Men\u00e9ndez C. Mefloquine for preventing malaria in pregnant women. Cochrane Database Syst Rev. 2018;11:Cd011444.","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-026-05963-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12936-026-05963-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-026-05963-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T15:08:34Z","timestamp":1787670514000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12936-026-05963-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,25]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5963"],"URL":"https:\/\/doi.org\/10.1186\/s12936-026-05963-4","relation":{},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,25]]},"assertion":[{"value":"15 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All data included in this analysis were obtained in accordance with the laws and ethical approvals applicable to the countries in which the studies were conducted, and were obtained with the knowledge and consent of the individual to whom they relate. Pseudonymised data which could not be traced back to individuals were shared with WWARN. This analysis does not require review of the Ethics\u00a0Committee under the guidelines of the Oxford Central University Research Ethics\u00a0Committee.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"GC works for DNDi who developed the first coformulation of AS-MQ. WRJT was employed by WHO-TDR previously, and was the study monitor for a trial of the AS-MQ FDC. Various authors worked on studies used to register the new FDC. EAA was Associate Editor at Malaria Journal from 2015\u20132025.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"308"}}